Polymorphisms of CYP2A6 and its practical consequences
- 1 October 2001
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 52 (4) , 357-363
- https://doi.org/10.1046/j.0306-5251.2001.01500.x
Abstract
CYP2A6 is an hepatic enzyme predominantly with some expression in specialized extrahepatic cell types. The CYP2A6 enzyme has a somewhat restricted active site, accepting only a few xenobiotics as substrates. Interest in CYP2A6 has risen considerably after nicotine and some tobacco specific nitrosamines were established as high‐affinity substrates for this enzyme. Recently, the organization and structures of the CYP2A gene cluster and several polymorphic alleles of the CYP2A6 gene have been characterized. Two alleles with a point mutation and at least three different types of gene deletion, all leading to deficient gene function, have been found. The frequencies of these alleles vary considerably among different ethnic populations, the deletion alleles being most common in Orientals (up to 20%). The frequency of point mutations are low in all populations studied thus far (< 3%). Several case‐control studies have addressed the relationship between CYP2A6 status and smoking habits as well as the role of CYP2A6 polymorphism in lung cancer risk. Studies in Japanese suggest that CYP2A6 poor metabolizer genotypes result in altered nicotine kinetics and may lower cigarette smoking elicited lung cancer risk, whereas similar studies in Caucasian populations have not revealed any clear associations between variant CYP2A6 genotypes and smoking behaviour or lung cancer predisposition.Keywords
This publication has 55 references indexed in Scilit:
- Expression of Biotransformation Enzymes in Human Fetal Olfactory Mucosa: Potential Roles in Developmental ToxicityToxicology and Applied Pharmacology, 2000
- Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolismFEBS Letters, 1999
- Metabolism of Methyl tert-butyl Ether and Other Gasoline Ethers by Human Liver Microsomes and Heterologously Expressed Human Cytochromes P450: Identification of CYP2A6 as a Major CatalystToxicology and Applied Pharmacology, 1999
- The Significance of the Homozygous CYP2A6 Deletion on Nicotine Metabolism: A New Genotyping Method of CYP2A6 Using a Single PCR–RFLPBiochemical and Biophysical Research Communications, 1999
- Characterization of Multiple Products of Cytochrome P450 2A6-Catalyzed Cotinine MetabolismChemical Research in Toxicology, 1999
- Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction methodPharmacogenetics, 1999
- GENETIC EPIDEMIOLOGY OF ENVIRONMENTAL TOXICITY AND CANCER SUSCEPTIBILITY: HUMAN ALLELIC POLYMORPHISMS IN DRUG-METABOLIZING ENZYME GENES, THEIR FUNCTIONAL IMPORTANCE, AND NOMENCLATURE ISSUESDrug Metabolism Reviews, 1999
- Metabolic capacity of nasal tissueMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997
- CYP2A6 gene polymorphism and risk of liver cancer and cirrhosisPharmacogenetics, 1997
- Interindividual variability of coumarin 7-hydroxylation in healthy volunteersPharmacogenetics, 1992